Over the years, PharmaMar has received numerous awards that recognize the efforts of the Company since its inception to advance cancer research and innovation in the marine biomedical space. The company has been honored with awards that show our commitment with our people, social responsibility, creativity and innovation.

The Company has been rated “excellent”, once again, in the call 2014 of the Profarma program, an initiative of the Ministry of Industry, Energy and Tourism to enhance the competitiveness of the pharmaceutical sector. This qualification has been maintained for more than 10 years.

leyenda_premios_ENG_v02

Prize
Entity
Year
XIV AECA Award for Business Transparency
Ministry of Industry, Energy and Tourism
2015
Plan PROFARMA Award for Excellence in Biotechnological R&D and Innovation
Ministry of Industry, Energy and Tourism
2013
ASPID Award for international campaign to relaunch Yondelis® in ovarian-cancer DLP®
ASPID
2013
National Innovation and Design Award for internationalization 2011
General Secretariat of Science, Technology and Innovation
2011
The Elsevier Galien Award to Yondelis® for “Best Pharmaceutical Product of the Year”
ELSEVIER GALIEN
2009
RX Silver Award
RX Club Show Prizes of New York
2008
The Elsevier Galien Award for Excellence in Biotechnological R&D
ELSEVIER-GALIEN
2008
Sarcoma Foundation of America Award for Commitment to Research into Soft Tissue Sarcoma
SARCOMA FOUNDATION OF AMERICA
2008
FundaMed-El Global Award to the Career of Jose María Fernández Sousa-Faro
FUNDAMED
2008

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.

Other Businesses

PharmaMar’s core business is oncology and it fully owns other companies that cover different aspects of healthcare and consumer chemical products.

Our History

Zeltia was founded in 1939. Since then, the Company has achieved several milestones in the field of the chemical and biopharmaceutical sectors. Of note, the authorization of the first marine-derived anticancer drug.